In a recent phase II study, the combination of erlotinib with entinostat, a selective HDAC inhibitor, showed promising results in prolonging progression-free survival in non-small cell lung cancer (NSCLC) patients with high E-cadherin levels, irrespective of their EGFR genotype [24]. Here, EGFR is linked to non-small cell lung carcinoma.